Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE)

• Status: Completed
• Trial end date: 2010-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Clinical trial of BAY43-9006 in patients with hepatocellular carcinoma.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer
• Treatments: Niacinamide; Sorafenib

Criteria

Inclusion Criteria:

• Male or female

• Aged of 18 and over

• Advanced hepatocellular carcinoma

Exclusion Criteria:

• History of prior systemic chemotherapy

• Failure in vital organ